The US Food and Drug Administration (FDA) has kept its new drug approvals for 2020 on track to match or best approvals in 2019, despite the COVID-19 pandemic.
By 4 December 2020, FDA had amassed a list of 48 new molecular entities and new therapeutic biological products approved by the agency’s Center for Drug Evaluation and Research (CDER), equaling the total for 2019. (RELATED: FDA: 2019 continues uptick in orphan drug approvals, Regulatory Focus 06 January 2020)
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,